Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
The ultra rapid delayed rectifier potassium current (IKur) is a specific type of voltage-gated potassium current found predominantly in atrial myocytes of the heart. It is primarily mediated by the Kv1.5 channel (encoded by the KCNA5 gene). IKur contributes to phase 1 and early phase 3 repolarization of the atrial action potential, which helps sets the refractory period and overall excitability of atrial cells. IKur's presence leads to a more triangular-shaped action potential waveform and shorter duration of action potentials in atria compared to ventricles. Selective blockade has been proposed as an antiarrhythmic strategy that targets only atria, potentially reducing pro-arrhythmic risk for ventricles.
IKur blockade
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Ultra Rapid Delayed Rectifier Potassium Current (IKur).